|Awarded On||February 19, 2020|
|Title||Molecular Features Impacting Drug Resistance in Atypical EGFR Exon 18 and Exon 20 Mutant NSCLC and the Development of Novel Mutant- Selective Inhibitors|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||John V Heymach|
|Cancer Sites||Lung and Bronchus|
*Pending contract negotiation
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality. Until recently, the primary treatment for advanced NSCLC has been chemotherapy, which typically causes significant tumor shrinkage in ~20% of patients, with significant toxicities. In recent years, however, the treatment of NSCLC has been revolutionized by two major changes: the development of targeted agents, such as tyrosine kinase inhibitors (TKIs) targeting mutant forms of epidermal growth factor receptor (EGFR); and immunotherapy. While these TKIs have been shown to dramatically prolong the lives of patients bearing “typical” EGFR mutations, approximately 20% of patients with EGFR mutations have “atypical” muta...